Molecular Formula | C16H20FN3O4 |
Molar Mass | 337.35 |
Density | 1.302±0.06 g/cm3(Predicted) |
Melting Point | 176-1780C |
Boling Point | 585.5±50.0 °C(Predicted) |
Specific Rotation(α) | D20 -9° (c = 0.919 in chloroform) |
Flash Point | 307.9°C |
Solubility | Soluble in water (<1 mg/mL at 25 °C), ethanol (8 mg/mL at 25 °C), chloroform, methano |
Vapor Presure | 1.08E-13mmHg at 25°C |
Appearance | White powder |
Color | white to off-white |
pKa | 15.53±0.46(Predicted) |
Storage Condition | room temp |
Refractive Index | 1.553 |
MDL | MFCD00937825 |
Use | Is a fully synthetic oxazolidinone antibiotic |
Hazard Symbols | Xn - Harmful |
Risk Codes | 20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S36 - Wear suitable protective clothing. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | AC2720000 |
HS Code | 29419000 |
Reference Show more | 1. [IF=3.631] Zhiya Yang et al."5-aminolevulinic acid-photodynamic therapy ameliorates cutaneous granuloma by killing drug-resistant Mycobacterium marinum."Photodiagn Photodyn. 2022 Mar;:102839 |
White Crystal, melting point 181.5~182.5 °c.
ethyl acetate, morpholine, and diisopropylethylamine were mixed, and 3,4-difluoro nitrobenzene was added dropwise with stirring, and the reaction was completed. Extracted with ethyl acetate, washed with saturated brine, dried, evaporated to dryness and recrystallized from acetone-water to give 3-fluoro-4-morpholinyl nitrobenzene. Mix reduced iron powder, water and glacial acetic acid, reflux for a certain time, Dropwise add 3 fluorine a 4 morpholino nitrobenzene anhydrous ethanol solution, after the reaction is finished, while hot filter, evaporated dry, the resulting material was extracted with ethyl acetate, washed with brine, dried and evaporated to dryness to give 3 monofluoro-4-morpholinylaniline. It is dissolved in the mixed solution of acetone and water, adding sodium bicarbonate, Dropwise adding benzyl chloroformate, stirring, Suction filtration, solid, filtrate into ice water, Suction filtration to obtain solid. The resulting solid was recrystallized from acetone-water to obtain benzyloxycarbonyl-3-fluoro-4-morpholinylaniline.
dissolve it in anhydrous Tetrahydrofuran, under the protection of ammonia, drop add butyl lithium solution, then drop add (R)-condensation of butyl ester, after reaction, add saturated ammonium chloride solution, ethyl acetate, water. The mixture was extracted with ethyl acetate, washed with saturated brine, dried and evaporated to dryness. The obtained material was dissolved in dichloromethane and triethylamine and reacted with methanesulfonyl chloride dropwise. Extraction with dichloromethane, washing with saturated brine, drying and evaporation gave the sulfonate. The sulfonic acid ester and sodium azide were dissolved in dimethylformamide for reaction. It is extracted with acetic acid ethanol, washed with saturated brine, dried, evaporated to dryness, and substituted to give the azide derivative. The derivative and 5% palladium-carbon were reacted in absolute ethanol for a certain time, filtered and evaporated to dryness. The obtained material was dissolved in tetrahydrofuran and aqueous sodium hydroxide solution, acetic anhydride was added, and extracted with ethyl acetate, saturated brine was washed with water and dried. Evaporation, silica gel column chromatography, ethyl acetate-n-hexane recrystallization, linezolid.
developed by Pharmacia & Upj ohn, Inc., USA, was first launched in the United States in April 2000. Antibiotics, inhibitors of bacterial protein synthesis. Linezolid on methicillin-sensitive or resistant staphylococcus, vancomycin-sensitive or resistant intestine
Bacteria, penicillin sensitive or resistant Pneumonia Streptococcus showed good antibacterial effect, also has antibacterial activity against anaerobic bacteria. Unlike other drugs, Linezolid does not affect peptidyl transferase activity. Linezolid has a unique site and mode of action, so it is not easy to cross resistance with other antibacterial drugs that inhibit protein synthesis in the positive bacteria with essential or acquired resistance characteristics, it is also not easy to induce the development of bacterial resistance in vitro. For vancomycin-resistant Enterococcus faecalis infection, concurrent and non-concurrent skin and skin structure infection.
overview | renezzoli (Linezolid Zyvox,U -100766,PNU-100766, linezolidone, linezolid, morpholidoxone, morpholidoxone) is a new type of azolidinone synthetic antibacterial drug developed and produced by Pharmacia & Upiohn Company (acquired by Pfizer), which was approved by FDA on April 18, 2000. This product is the first drug approved for the treatment of methicillin-resistant Staphylococcus aureus infection in the United States in 40 years. It was listed in my country in September 2007 and belongs to medical insurance Class B drugs. |
Indications | Used to treat infections caused by gram-positive (G) cocci, including concurrent bacteremia; Hospital-acquired pneumonia; Community-acquired pneumonia (Pneumonia is clinically divided into hospital-acquired pneumonia and community-acquired pneumonia due to different pathogenic bacteria.) and concomitant bacteremia; complex skin and skin soft tissue infections, including diabetic foot infections complicated with osteomyelitis; non-complex skin and skin soft tissue infections; treatment of vancomycin-resistant Enterococcus faecium infection. |
use | is a fully synthetic oxazolidinone antibiotic oxazolidinone antibacterial drug antipyretic and analgesic bulk drug inhibit bacterial mRNA translation. |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |